Biotts
PrivateLast Round
Accelerator
Oct 5, 2021
Total Funding Raised
$3.64M
Company Overview
Biotts operates in Healthcare & Life Sciences and is based in Bielany Wrocławskie. Its latest recorded funding round was an Accelerator round in October 2021.
Biotts is a Poland-based biotechnology company that develops proprietary drug delivery technologies and drug formulas in the fields of oncology, dermatology, and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical Devices
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Biotts Comparables
Compare Biotts with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Anodyne Nanotech | 85% | |
| Dyve Biosciences | 79% | |
| Axcelead, Inc. | 77% |
For institutional investors. Book with your work email.
Biotts Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Oct 5, 2021 | ||||
| VC Round | Mar 22, 2020 | ||||
| Grant | Dec 20, 2019 | ||||
| Grant | Aug 1, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Biotts Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Montis Capital | Grant |
| Google for Startups Accelerator | Accelerator |
| Montis Capital | VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 3, 2026
Monthly visitors grew 152% MoM.
- Mar 2, 2026
Monthly visitors increased 282% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingNov 3, 2026
Biotts receives $6.39M in a pre-IPO round led by Mariusz Książek from private investors and family offices to develop its MTC-Y drug-delivery platform and diabetes and obesity projects.
For institutional investors. Book with your work email.
Biotts Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Biotts's valuation, stock price, and market status.
Is Biotts a public or private company?
Biotts is a private company.
What is the current stock price of Biotts?
Biotts is a private company, so its shares have no public market price. Caplight tracks Biotts's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Biotts worth (valuation)?
Valuation information for Biotts is not publicly available.
Can I buy Biotts stock?
Biotts shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Biotts's last funding round?
Biotts's most recent funding round was Accelerator on October 5, 2021.
Who are the main investors in Biotts?
Key investors in Biotts include Montis Capital.
Will Biotts IPO soon?
No public IPO plans have been announced for Biotts.
How can I track Biotts secondary market activity?
Caplight tracks bids, offers, and trades in Biotts's shares on secondary markets.